FibroBiologics Inc. Commo... (FBLG)
1.15
-0.11 (-8.73%)
At close: Mar 03, 2025, 3:59 PM
1.15
-0.43%
Pre-market: Mar 04, 2025, 08:53 AM EST
Company Description
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States.
It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing.
The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers.
FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FibroBiologics Inc. Common Stock
| Country | United States |
| IPO Date | Feb 1, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Peter O'Heeron |
Contact Details
Address: 455 East Medical Center Boulevard Houston, Delaware United States | |
| Website | https://www.fibrobiologics.com |
Stock Details
| Ticker Symbol | FBLG |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001958777 |
| CUSIP Number | 31573L105 |
| ISIN Number | US31573L1052 |
| Employer ID | 86-3329066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter O'Heeron | Founder, Chairperson & Chief Executive Officer |
| Robert E. Hoffman B.B.A., CPA | Interim Chief Financial Officer & Director |
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Ruben A. Garcia J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Feb 07, 2025 | 8-K | Current Report |
| Feb 03, 2025 | S-3 | Filing |
| Jan 30, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 29, 2025 | SCHEDULE 13G | Filing |
| Jan 24, 2025 | 8-K | Current Report |
| Jan 17, 2025 | POS AM | Filing |
| Jan 14, 2025 | 424B4 | Filing |
| Jan 10, 2025 | S-1/A | [Amend] Filing |
| Dec 31, 2024 | 8-K | Current Report |